Feds Upgrade ‘Healthfinder’ Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 6
Volume 7
Issue 6

WASHINGTON--The government has upgraded its health information website, "healthfinder," adding two new sections: "Smart Choices," to tell people how to find reliable health information on the Internet, and "Just for You," to tailor information by age and ethnicity, with the aim of enabling consumers to seek information geared to children or aging parents, for example. The website can be reached at www.healthfinder.gov.

WASHINGTON--The government has upgraded its health information website, "healthfinder," adding two new sections: "Smart Choices," to tell people how to find reliable health information on the Internet, and "Just for You," to tailor information by age and ethnicity, with the aim of enabling consumers to seek information geared to children or aging parents, for example. The website can be reached at www.healthfinder.gov.

Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Related Content